Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Traynor Capital Management Inc.

Traynor Capital Management Inc. boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1,038.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,762 shares of the pharmaceutical company’s stock after buying an additional 5,256 shares during the quarter. Traynor Capital Management Inc.’s holdings in Vertex Pharmaceuticals were worth $2,320,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of VRTX. Baker Ellis Asset Management LLC raised its stake in Vertex Pharmaceuticals by 43.4% in the fourth quarter. Baker Ellis Asset Management LLC now owns 1,058 shares of the pharmaceutical company’s stock valued at $426,000 after buying an additional 320 shares in the last quarter. Park Place Capital Corp increased its position in shares of Vertex Pharmaceuticals by 10.9% during the fourth quarter. Park Place Capital Corp now owns 365 shares of the pharmaceutical company’s stock worth $147,000 after purchasing an additional 36 shares in the last quarter. Albion Financial Group UT lifted its holdings in shares of Vertex Pharmaceuticals by 3.2% in the 4th quarter. Albion Financial Group UT now owns 1,340 shares of the pharmaceutical company’s stock valued at $540,000 after purchasing an additional 42 shares during the last quarter. Advisory Alpha LLC increased its holdings in shares of Vertex Pharmaceuticals by 10.0% in the 4th quarter. Advisory Alpha LLC now owns 1,292 shares of the pharmaceutical company’s stock valued at $520,000 after acquiring an additional 117 shares during the period. Finally, MBM Wealth Consultants LLC increased its stake in Vertex Pharmaceuticals by 4.9% in the fourth quarter. MBM Wealth Consultants LLC now owns 2,664 shares of the pharmaceutical company’s stock valued at $1,081,000 after purchasing an additional 124 shares during the period. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Up 0.0 %

Shares of NASDAQ VRTX opened at $428.00 on Thursday. The business has a 50 day simple moving average of $438.10 and a 200-day simple moving average of $465.39. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.77. The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. Vertex Pharmaceuticals’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.67 earnings per share. Analysts expect that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current year.

Wall Street Analyst Weigh In

VRTX has been the subject of a number of analyst reports. Royal Bank of Canada increased their target price on Vertex Pharmaceuticals from $437.00 to $451.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. Cantor Fitzgerald reiterated an “overweight” rating and set a $480.00 price target on shares of Vertex Pharmaceuticals in a research report on Tuesday, November 5th. Morgan Stanley upped their price target on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Oppenheimer cut Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, December 19th. Finally, Wells Fargo & Company lowered their target price on Vertex Pharmaceuticals from $555.00 to $460.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $490.38.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.